CUMBERLAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2025 and 2024
| 2025 | 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $11,444,693 | $17,964,184 |
| Accounts receivable, net | 16,944,780 | 11,701,466 |
| Inventories, net | 6,225,518 | 3,999,995 |
| Prepaid and other current assets | 2,445,276 | 2,786,513 |
| Total current assets | 37,060,267 | 36,452,158 |
| Non-current inventories | 9,253,090 | 11,005,499 |
| Property and equipment, net | 264,724 | 277,365 |
| Intangible assets, net | 14,027,921 | 17,973,449 |
| Goodwill | 914,000 | 914,000 |
| Operating lease right-of-use assets | 8,343,832 | 6,176,923 |
| Investment in co-commercialization | 3,986,780 | — |
| Other assets | 2,973,378 | 2,784,016 |
| Total assets | $76,823,992 | $75,583,410 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $18,567,546 | $13,914,266 |
| Operating lease current liabilities | 467,774 | 356,508 |
| Revolving line of credit - current | — | 5,100,000 |
| Other investment liabilities | 5,074,504 | — |
| Other current liabilities | 12,635,095 | 12,250,955 |
| Total current liabilities | 36,744,919 | 31,621,729 |
| Revolving line of credit - long term | 5,240,733 | 10,176,170 |
| Operating lease non-current liabilities | 4,471,965 | 4,939,739 |
| Other long-term liabilities | 5,822,153 | 6,299,795 |
| Total liabilities | 52,279,770 | 53,037,433 |
| Equity: | ||
| Shareholders’ equity: | ||
| Common stock – no par value; 100,000,000 shares authorized; 14,956,627 and 13,952,624 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 51,684,381 | 46,821,425 |
| Accumulated deficit | (26,804,059) | (23,967,931) |
| Total shareholders’ equity | 24,880,322 | 22,853,494 |
| Noncontrolling interests | (336,100) | (307,517) |
| Total equity | 24,544,222 | 22,545,977 |
| Total liabilities and equity | $76,823,992 | $75,583,410 |
See accompanying notes to consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.